<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-130748" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Atezolizumab</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Aleem</surname>
            <given-names>Abdul</given-names>
          </name>
          <aff>Lehigh Valley Health Network, Allentown, USA</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Shah</surname>
            <given-names>Hiral</given-names>
          </name>
          <aff>Lehigh Valley Health Network</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Abdul Aleem declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Hiral Shah declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>29</day>
          <month>10</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-130748.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Atezolizumab is a humanized IgG1 monoclonal antibody&#x000a0;that targets programmed cell death ligand 1 (PD-L1). Atezolizumab&#x000a0;has received FDA approval for multiple neoplastic conditions and may be administered as monotherapy or in combination with chemotherapy. Indications include locally advanced or metastatic urothelial carcinoma, metastatic non-small cell lung cancer, extensive-stage small cell lung cancer, metastatic triple-negative breast cancer, and unresectable or metastatic hepatocellular carcinoma.</p>
        <p>This activity reviews the various pharmacological features of atezolizumab, including the mechanism of action and dosage adjustments. Additionally, warnings, precautions, and monitoring parameters are emphasized to ensure optimal patient outcomes. Adverse events and contraindications are also highlighted to guide clinicians in minimizing risks associated with atezolizumab therapy. Improved care coordination between interprofessional team members is essential to maximize the therapeutic benefits&#x000a0;for patients receiving this medication.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of atezolizumab.</p></list-item><list-item><p>Assess the adverse effects&#x000a0;associated with atezolizumab administration.</p></list-item><list-item><p>Determine monitoring parameters for immune-mediated adverse reactions&#x000a0;encountered&#x000a0;during atezolizumab therapy.</p></list-item><list-item><p>Determine&#x000a0;the importance of an interprofessional team approach and care coordination when treating patients with atezolizumab.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=130748&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=130748">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-130748.s2" sec-type="Indications">
        <title>Indications</title>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p>Atezolizumab is a humanized IgG1 monoclonal anti-programmed cell death ligand 1 (PD-L1) antibody that has been approved by the U.S. Food Drug Administration (FDA) for various neoplastic conditions as a single agent or in combination with other chemotherapeutic agents. These FDA-approved indications are discussed below.<xref ref-type="bibr" rid="article-130748.r1">[1]</xref></p>
        <p>
<bold>Extensive-stage small-cell lung cancer</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>A combination of atezolizumab, carboplatin, and etoposide is the first-line treatment&#x000a0;for adults with extensive-stage small-cell lung cancer.<xref ref-type="bibr" rid="article-130748.r2">[2]</xref></p>
          </list-item>
        </list>
        <p><bold>Non&#x02013;small-cell lung cancer</bold>
<bold>(NSCLC)</bold>&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Atezolizumab&#x000a0;monotherapy is&#x000a0;administered as adjuvant therapy following resection and platinum-based chemotherapy for adults with stage II to IIIA&#x000a0;NSCLC&#x000a0;and&#x000a0;PD-L1 expression on &#x02265;1% of tumor cells (confirmed by an FDA-approved test).</p>
          </list-item>
          <list-item>
            <p>Atezolizumab monotherapy is indicated&#x000a0;for patients with metastatic NSCLC with high PD-L1 expression, regardless of histologic type. These patients are confirmed by an FDA-approved test and have no EGFR or ALK genomic tumor aberrations.&#x000a0;
<list list-type="bullet"><list-item><p>PD-L1 stained &#x02265;50% of tumor cells (TC &#x02265;50%)</p></list-item><list-item><p>PD-L1 stained tumor-infiltrating immune cells (IC) covering &#x02265;10% of the tumor area (IC &#x02265;10%)</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>A combination&#x000a0;of atezolizumab and bevacizumab plus chemotherapy (eg, paclitaxel and carboplatin) is the first-line treatment&#x000a0;for adults with metastatic non-squamous NSCLC regardless of PD-L1 expression and epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor alterations.</p>
          </list-item>
          <list-item>
            <p>A combination of atezolizumab&#x000a0;and nanoparticle albumin-bound paclitaxel and carboplatin is the first-line treatment of adults with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations.</p>
          </list-item>
          <list-item>
            <p>Atezolizumab monotherapy is indicated for treating adult patients with metastatic NSCLC who have disease progression during or despite receiving platinum-based chemotherapy.<xref ref-type="bibr" rid="article-130748.r2">[2]</xref><xref ref-type="bibr" rid="article-130748.r3">[3]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Unresectable&#x000a0;or metastatic hepatocellular carcinoma&#x000a0;</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>A combination&#x000a0;of atezolizumab and bevacizumab is indicated for patients with unresectable or metastatic hepatocellular carcinoma (HCC) who have not previously&#x000a0;undergone chemotherapy.<xref ref-type="bibr" rid="article-130748.r4">[4]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Unresectable or metastatic melanoma</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>A combination of atezolizumab, vemurafenib, and cobimetinib is indicated for patients with BRAF mutation-positive unresectable or metastatic melanoma.<xref ref-type="bibr" rid="article-130748.r5">[5]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Alveolar soft part sarcoma</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>&#x000a0;Atezolizumab monotherapy is indicated for treating unresectable or metastatic alveolar soft part sarcoma (ASPS) in adults and&#x000a0;children aged 2 and older.</p>
          </list-item>
        </list>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <p>
<bold>Metastatic triple-negative breast cancer</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>A combination of atezolizumab and nanoparticle albumin-bound paclitaxel may be administered off-label&#x000a0;to&#x000a0;treat adults with unresectable locally advanced or metastatic triple-negative breast cancer whose tumors express PD-L1.<xref ref-type="bibr" rid="article-130748.r6">[6]</xref></p>
          </list-item>
        </list>
        <p><bold>Locally advanced or metastatic urothelial carcinoma</bold>&#x000a0;</p>
        <p>Atezolizumab monotherapy is indicated&#x000a0;for patients with locally advanced or metastatic urothelial carcinoma who:</p>
        <list list-type="bullet">
          <list-item>
            <p>Are ineligible for cisplatin-containing chemotherapy with a level of tumor PD-L1 expression, or</p>
          </list-item>
          <list-item>
            <p>Are ineligible for any platinum-containing chemotherapy irrespective of their PD-L1expression status, or</p>
          </list-item>
          <list-item>
            <p>Exhibit&#x000a0;disease progression during or following any platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant chemotherapy&#x000a0;<xref ref-type="bibr" rid="article-130748.r7">[7]</xref><xref ref-type="bibr" rid="article-130748.r8">[8]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-130748.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Many immune and tumor-infiltrating cells express programmed cell death-ligand 1 (PD-L1), which negatively regulates the activation of cytotoxic T lymphocytes by binding to the programmed death-1 (PD-1) and B7.1 (CD80) receptors that cause suppression of T-cell migration, proliferation, and secretion of cytotoxic mediators, leading to inhibited tumor cell killing.<xref ref-type="bibr" rid="article-130748.r9">[9]</xref></p>
        <p>Data from&#x000a0;various clinical trials have shown that agents targeting the PD-L1/PD-1 molecular pathway can induce antitumor activity early and across multiple neoplastic conditions. Atezolizumab is a humanized monoclonal anti-programmed death-ligand 1 (PD-L1) antibody that inhibits PD-L1&#x02013;programmed death 1 (PD-1) PD-L1&#x02013;B7-1 signaling,&#x000a0;preventing tumor-specific cytotoxic T-cell immunity and allowing (or inducing) the normal pathway of tumor cell killing to proceed.<xref ref-type="bibr" rid="article-130748.r10">[10]</xref></p>
      </sec>
      <sec id="article-130748.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms and Strengths</bold>
</p>
        <p>Atezolizumab is available as a 15-mL subcutaneous injection&#x000a0;containing 1,875 mg of atezolizumab and 30,000 units of hyaluronidase (TECENTRIQ HYBREZA). Atezolizumab&#x000a0;is also available in 2 intravenous, single-dose solutions:</p>
        <list list-type="bullet">
          <list-item>
            <p>TECENTRIQ 840 mg/14 mL (60 mg/mL)</p>
          </list-item>
          <list-item>
            <p>TECENTRIQ 1200 mg/20 mL (60 mg/mL)</p>
          </list-item>
        </list>
        <p>
<bold>Adult Dosage</bold>
</p>
        <p>TECENTRIQ HYBREZA (SQ): Remove the vial from the refrigerator and allow the atezolizumab solution to acclimate to room temperature. Discard the vial if the solution is discolored, cloudy, or visible particles are observed. Do not freeze, shake, or dilute at any point in time. The unpunctured vial can be stored at room temperature under&#x000a0;ambient lighting for a maximum of 4 hours before preparation for administration. After priming the administration needle, expel excess from the syringe to ensure it contains exactly 15 mL of&#x000a0;solution and administer it immediately to avoid needle clogging.</p>
        <list list-type="bullet">
          <list-item>
            <p>Do&#x000a0;not&#x000a0;store the prepared syringe attached to a primed subcutaneous administration set.</p>
          </list-item>
          <list-item>
            <p>The capped syringe may be stored at room temperature (up to 25 &#x000b0;C in ambient room lighting) for up to 8 hours or in the refrigerator (2 &#x000b0;C to 8 &#x000b0;C) for up to 72 hours, allowing&#x000a0;it to acclimate to room temperature before administration.</p>
          </list-item>
        </list>
        <p>TECENTRIQ (IV): Injection vials should be diluted with 0.9 % sodium chloride injection. Mix the&#x000a0;solution with gentle inversion, and do not shake it.&#x000a0;Administer the diluted solution immediately once dispensed. If the diluted infusion solution is not used immediately, store it at room temperature for no more than 6 hours from the dilution, including time for administering the infusion.&#x000a0;The dilution can be refrigerated at 2 to 8 &#x000b0;C for no more than 24 hours after being prepared; it should not be&#x000a0;frozen. The initial infusion should&#x000a0;occur over 60 minutes; if this is well tolerated, subsequent doses can be administered over 30 minutes. Patients should be closely monitored for infusion-related reactions. Severe reactions are indications&#x000a0;to temporarily interrupt, slow, or permanently discontinue the infusion.</p>
        <p>
<bold>IV infusion (monotherapy)&#x000a0;</bold>
</p>
        <p>For most indicated cancers, the dose is generally 1200 mg every&#x000a0;3 weeks.&#x000a0;For unresectable or metastatic melanoma, the dose is 840 mg every&#x000a0;2 weeks. However, depending on the diagnosis and institution, the dose can vary from this standard regimen. The clinician should always consult the drug package insert and institutional protocols before&#x000a0;determining a dosing regimen for any patient. The following dosing recommendations are valid unless disease progression (or recurrence) or unacceptable toxicity is encountered.</p>
        <p>Metastatic NSCLC:</p>
        <list list-type="bullet">
          <list-item>
            <p>840 mg every&#x000a0;2 weeks, or</p>
          </list-item>
          <list-item>
            <p>1200 mg every&#x000a0;3 weeks, or</p>
          </list-item>
          <list-item>
            <p>1680 mg every&#x000a0;4 weeks</p>
          </list-item>
        </list>
        <p>Adjuvant treatment of NSCLC: Up to 1 year</p>
        <list list-type="bullet">
          <list-item>
            <p>840 mg every&#x000a0;2 weeks, or</p>
          </list-item>
          <list-item>
            <p>1200 mg every&#x000a0;3 weeks, or</p>
          </list-item>
          <list-item>
            <p>1680 mg every&#x000a0;4 weeks</p>
          </list-item>
        </list>
        <p>Adults with ASPS:</p>
        <list list-type="bullet">
          <list-item>
            <p>840 mg every&#x000a0;2 weeks, or</p>
          </list-item>
          <list-item>
            <p>1200 mg every&#x000a0;3 weeks, or</p>
          </list-item>
          <list-item>
            <p>1680 mg every&#x000a0;4 weeks</p>
          </list-item>
        </list>
        <p>
<bold>IV infusion (in combination therapy)</bold>
</p>
        <p>NSCLC: Administer atezolizumab before chemotherapy and bevacizumab when given on the same day until disease progression or unacceptable toxicity.</p>
        <list list-type="bullet">
          <list-item>
            <p>840 mg every&#x000a0;2 weeks, or</p>
          </list-item>
          <list-item>
            <p>1200 mg every&#x000a0;3 weeks, or</p>
          </list-item>
          <list-item>
            <p>1680 mg every&#x000a0;4 weeks</p>
          </list-item>
        </list>
        <p>SCLC: Administer atezolizumab before chemotherapy when given on the same day.</p>
        <list list-type="bullet">
          <list-item>
            <p>840 mg every&#x000a0;2 weeks, or</p>
          </list-item>
          <list-item>
            <p>1200 mg every&#x000a0;3 weeks, or</p>
          </list-item>
          <list-item>
            <p>1680 mg every&#x000a0;4 weeks</p>
          </list-item>
        </list>
        <p>HCC: Administer atezolizumab before bevacizumab when given on the same day. Bevacizumab is administered at 15 mg/kg every&#x000a0;3 weeks.</p>
        <list list-type="bullet">
          <list-item>
            <p>840 mg every&#x000a0;2 weeks, or</p>
          </list-item>
          <list-item>
            <p>1200 mg every&#x000a0;3 weeks, or</p>
          </list-item>
          <list-item>
            <p>1680 mg every&#x000a0;4 weeks</p>
          </list-item>
        </list>
        <p>Melanoma: Administer atezolizumab&#x000a0;with cobimetinib 60 mg orally once daily (21 days on and&#x000a0;7 days off) and vemurafenib 720 mg orally twice daily.&#x000a0;Before initiating atezolizumab,&#x000a0;patients should receive a 28-day treatment cycle of cobimetinib 60 mg orally once daily (21 days on and 7 days off) and vemurafenib 960 mg orally twice daily from Days 1 to 21 and vemurafenib 720 mg orally twice daily from Days 22 to 28.</p>
        <list list-type="bullet">
          <list-item>
            <p>840 mg every&#x000a0;2 weeks, or</p>
          </list-item>
          <list-item>
            <p>1200 mg every&#x000a0;3 weeks, or</p>
          </list-item>
          <list-item>
            <p>1680 mg every&#x000a0;4 weeks</p>
          </list-item>
        </list>
        <p><bold>SQ injection</bold>&#x000a0;</p>
        <p>This is administered subcutaneously in the thigh over approximately 7 minutes every 3 weeks.&#x000a0;</p>
        <p>NSCLC: Administer as monotherapy for up to&#x000a0;1 year unless there is disease recurrence or unacceptable toxicity.</p>
        <p>Metastatic NSCLC: Administer atezolizumab as monotherapy for up to&#x000a0;1 year until disease progression or unacceptable toxicity.</p>
        <p>NSCLC: Administer atezolizumab before chemotherapy and bevacizumab when given on the same day. Treat until disease progression or unacceptable toxicity.</p>
        <p>SCLC: Administer atezolizumab before chemotherapy when given on the same day.&#x000a0;Treat until disease progression or unacceptable toxicity.</p>
        <p>HCC: Administer atezolizumab before bevacizumab when given on the same day. Bevacizumab is administered intravenously at 15 mg/kg every 3 weeks.&#x000a0;Treat until disease progression or unacceptable toxicity.</p>
        <p>Melanoma: Before initiating atezolizumab, patients should receive the following 28-day cobimetinib and vemurafenib treatment cycle.&#x000a0;Treat until disease progression or unacceptable toxicity.</p>
        <list list-type="bullet">
          <list-item>
            <p>Days 1 to 21: cobimetinib 60 mg orally once daily in combination with 960 mg of oral vemurafenib twice daily</p>
          </list-item>
          <list-item>
            <p>Days 22 to 28: withhold cobimetinib and administer vemurafenib 720 mg orally twice daily</p>
          </list-item>
        </list>
        <p>ASPS: Administer atezolizumab monotherapy until disease progression or unacceptable toxicity.</p>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Pregnancy considerations:</bold> Before starting treatment with atezolizumab, confirm the pregnancy status of women who could become pregnant. Inform these women about the possible risks to a fetus and recommend the use of effective contraception during treatment and for&#x000a0;5 months following the last dose.&#x000a0;There is a lack of data regarding its use in pregnancy. However, based on its mechanism of action, it can potentially cause fetal harm. Animal studies show that blocking the PD-L1/PD-1 pathway could enhance the possibility of immune-related rejection of the fetus, leading to fetal death.</p>
        <p><bold>Breastfeeding considerations:</bold> Breastfeeding is not recommended while on therapy with atezolizumab and at least for 5 months after the last dose.</p>
        <p><bold>Pediatric patients:</bold>&#x000a0;The dosage for children aged 2 and older with ASPS is 15 mg/kg (maximum 1200 mg) every&#x000a0;3 weeks.</p>
      </sec>
      <sec id="article-130748.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>As with other approved PD-1/PD-L1-targeted therapies, the&#x000a0;administration of atezolizumab can be associated with immune-mediated adverse events (imAEs), which can be severe or fatal and involve any organ system manifesting as described below.<xref ref-type="bibr" rid="article-130748.r11">[11]</xref><xref ref-type="bibr" rid="article-130748.r12">[12]</xref><xref ref-type="bibr" rid="article-130748.r13">[13]</xref></p>
        <p>
<bold>Infusion-related reactions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Anaphylaxis and hypersensitivity</p>
          </list-item>
        </list>
        <p>
<bold>Immune-mediated colitis</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Immune-mediated colitis is characterized by signs and symptoms of diarrhea or increased ostomy output, colitis, or perforation. All other etiologies of diarrhea and colitis should be excluded, including endoscopic evaluation.&#x000a0;Based on the clinical and endoscopic severity, immune-mediated colitis is classified into&#x000a0;4&#x000a0;grades:
<list list-type="bullet"><list-item><p>Grade 1: &#x0003c;4 stools per day or mild increase in ostomy output compared to baseline</p></list-item><list-item><p>Grade 2: 4&#x000a0;to 6 stools per day or moderate increase in ostomy output compared to baseline (compared with baseline) or colitis symptoms</p></list-item><list-item><p>Grade 3: &#x02265;7 stools per day or severe increase in ostomy output compared to baseline with colitis</p></list-item><list-item><p>Grade 4: Severe colitis resulting in bowel perforation requiring urgent surgical intervention</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Immune-mediated cutaneous adverse effects</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Immune-mediated cutaneous adverse reactions are common and manifest as itching, maculopapular rash, lichenoid reactions, vitiligo, and pruritus.</p>
          </list-item>
          <list-item>
            <p>Based on the clinical severity and percentage of involvement of the body surface area, they are classified into&#x000a0;4 grades:
<list list-type="bullet"><list-item><p>Grade 1: asymptomatic with macules/papules involving &#x0003c;10% of the body surface area</p></list-item><list-item><p>Grade 2: macules/papules involving 10%&#x000a0;to 30% of the body surface area with or without symptoms</p></list-item><list-item><p>Grade 3: macules/papules involving &#x0003e;30% of the body surface area with or without symptoms</p></list-item><list-item><p>Grade 4: Severe cutaneous reactions such as Stevens-Johnson syndrome, TEN, and bullous dermatitis covering &#x0003e;30% of BSA and requiring intensive care unit (ICU) admission</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Immune-mediated endocrinopathies</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Immune-mediated endocrinopathies can present with signs and symptoms of adrenal insufficiency, thyroiditis, hypothyroidism, hypothyroidism, hypophysitis, and diabetes, either alone related to one endocrine organ or in combination.</p>
          </list-item>
        </list>
        <p>
<bold>Immune-mediated hepatitis</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Immune-mediated hepatitis typically manifests with elevated liver function markers.</p>
          </list-item>
          <list-item>
            <p>Based on the severity of liver test abnormalities and hepatic dysfunction, immune-mediated hepatitis is classified into&#x000a0;4&#x000a0;grades:
<list list-type="bullet"><list-item><p>Grade 1: Elevation of AST/ALT &#x0003c;3&#x000a0;times (3x) the upper limit of normal (ULN) or total bilirubin &#x0003c;1.5x ULN</p></list-item><list-item><p>Grade 2: Elevation of AST/ALT 3x to 5x ULN or total bilirubin &#x0003e;1.5 to &#x02264;&#x02009;3x ULN</p></list-item><list-item><p>Grade 3: Elevation of AST/ALT &#x0003e;5x to 20x ULN or total bilirubin 3 to 10x ULN</p></list-item><list-item><p>Grade 4: AST/ALT &#x0003e;&#x02009;20x ULN or total bilirubin &#x0003e;10x ULN (with signs and symptoms of liver dysfunction)</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Immune-mediated pneumonitis or interstitial lung disease</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Immune-mediated pneumonitis is characterized by a nonproductive cough, shortness of breath, and radiological abnormalities of the lung.</p>
          </list-item>
          <list-item>
            <p>Based on clinical severity and radiological involvement, immune-mediated pneumonitis is classified into 4 grades:&#x000a0;
<list list-type="bullet"><list-item><p>Grade 1: asymptomatic and limited to &#x0003c;25% involvement of the lung parenchyma or&#x000a0;1 lobe of the lung</p></list-item><list-item><p>Grade 2: moderate symptoms and involvement of 25% to 50% of the lung parenchyma or more than&#x000a0;1 lobe of the lung</p></list-item><list-item><p>Grade 3: severe symptoms and involvement of &#x0003e;50% of the lung parenchyma or all lung lobes</p></list-item><list-item><p>Grade 4: acute respiratory distress requiring mechanical ventilation</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Immune-mediated renal dysfunction and nephritis</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Immune-mediated renal dysfunction typically manifests with increased creatinine levels and is graded into&#x000a0;4 types based on renal function:&#x000a0;
<list list-type="bullet"><list-item><p>Grade 1: An increase in creatinine level &#x0003e;0.3 mg/dL or 1.5&#x000a0;to 2.0 times compared to&#x000a0;the patient's&#x000a0;baseline value</p></list-item><list-item><p>Grade 2: An increase in creatinine level 2x to 3x baseline</p></list-item><list-item><p>Grade 3: An increase in creatinine level &#x0003e;4.0 mg/dL or &#x0003e;3x baseline</p></list-item><list-item><p>Grade 4: Worsening renal function requiring hemodialysis</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Immune-mediated neurological toxicities</bold>
<bold/>
</p>
        <p>The incidence of immune-mediated neurological toxicity is 1% and is characterized by polyneuropathy, facial nerve palsy, aseptic meningitis, transverse myelitis, myasthenia gravis, Guillain-Barr&#x000e9; syndrome (GBS), or posterior reversible leukoencephalopathy.</p>
        <p>Other common adverse reactions that occurred&#x000a0;in patients receiving&#x000a0;atezolizumab&#x000a0;monotherapy&#x000a0;during clinical trials are listed by system below.<xref ref-type="bibr" rid="article-130748.r14">[14]</xref><xref ref-type="bibr" rid="article-130748.r2">[2]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Musculoskeletal: back pain, neck pain</p>
          </list-item>
          <list-item>
            <p>Metabolic: decreased appetite, hyperglycemia, hyponatremia, hyperkalemia, hypermagnesemia, hypophosphatemia</p>
          </list-item>
          <list-item>
            <p>Dermatologic: pruritus, rash</p>
          </list-item>
          <list-item>
            <p>Respiratory: cough, dyspnea</p>
          </list-item>
          <list-item>
            <p>General: fatigue, pyrexia, asthenia</p>
          </list-item>
          <list-item>
            <p>Gastrointestinal: abdominal pain, diarrhea, constipation, nausea</p>
          </list-item>
          <list-item>
            <p>Endocrine: hypothyroidism</p>
          </list-item>
          <list-item>
            <p>Infectious: pneumonia, urinary tract infection</p>
          </list-item>
          <list-item>
            <p>Blood/lymphatic: decreased hemoglobin, anemia, thrombocytopenia, lymphopenia</p>
          </list-item>
          <list-item>
            <p>Hepatobiliary: elevated liver function markers</p>
          </list-item>
          <list-item>
            <p>Renal: elevated serum creatinine</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-130748.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>
<bold>Contraindications</bold>
</p>
        <p>TECENTRIQ HYBREZA should not be used in individuals with a known allergy to hyaluronidase or any of its components.</p>
        <p>
<bold>Warnings/Precautions</bold>
</p>
        <p>
<bold>Immune-mediated adverse reactions</bold>
</p>
        <p>Pneumonitis:</p>
        <list list-type="bullet">
          <list-item>
            <p>Grade 2: Withhold<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a617b089-ce66-464b-987b-b45d029b4d6f#footnote-2">*</ext-link></p>
          </list-item>
          <list-item>
            <p>Grade 3 or 4: Permanently discontinue</p>
          </list-item>
        </list>
        <p>Colitis:</p>
        <list list-type="bullet">
          <list-item>
            <p>Grade 2 or 3: Withhold<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a617b089-ce66-464b-987b-b45d029b4d6f#footnote-2">*</ext-link></p>
          </list-item>
          <list-item>
            <p>Grade 4: Permanently discontinue</p>
          </list-item>
        </list>
        <p>Hepatitis with no liver tumor:</p>
        <list list-type="bullet">
          <list-item>
            <p>AST or ALT&#x000a0;&#x0003e;3x and &#x0003c;8x ULN, or total bilirubin &#x0003e;1.5x and &#x0003c;3x ULN: Withhold<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a617b089-ce66-464b-987b-b45d029b4d6f#footnote-2">*</ext-link></p>
          </list-item>
          <list-item>
            <p>AST or ALT &#x0003e;8x ULN, or total bilirubin &#x0003e;3x ULN: Permanently discontinue</p>
          </list-item>
        </list>
        <p>Hepatitis with liver tumor:</p>
        <list list-type="bullet">
          <list-item>
            <p>Baseline AST or ALT is &#x0003e;1x and &#x0003c;3x ULN and increases to &#x0003e;5x and &#x0003c;10x ULN, or baseline AST or ALT is &#x0003e;3x and &#x0003c;5x ULN and increases to &#x0003e;8x and &#x0003c;10x ULN: Withhold<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a617b089-ce66-464b-987b-b45d029b4d6f#footnote-2">*</ext-link></p>
          </list-item>
          <list-item>
            <p>AST or ALT increases to &#x0003e;10x ULN, or total bilirubin increases to &#x0003e;3x ULN: Permanently discontinue</p>
          </list-item>
          <list-item>
            <p>If baseline AST and ALT &#x02264;ULN: withhold or permanently discontinue (based on recommendations for hepatitis with no liver involvement)</p>
          </list-item>
        </list>
        <p>Endocrinopathy:</p>
        <list list-type="bullet">
          <list-item>
            <p>Grade 3 or 4: Hold until clinically stable or permanently discontinue (depending on severity)</p>
          </list-item>
        </list>
        <p>Nephritis with renal dysfunction:</p>
        <list list-type="bullet">
          <list-item>
            <p>Grade 2 or 3 creatinine elevation: Withhold<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a617b089-ce66-464b-987b-b45d029b4d6f#footnote-2">*</ext-link></p>
          </list-item>
          <list-item>
            <p>Grade 4 creatinine elevation: Permanently discontinue</p>
          </list-item>
        </list>
        <p>Exfoliative dermatologic conditions:</p>
        <list list-type="bullet">
          <list-item>
            <p>Suspected SJS, TEN, or DRESS:&#x000a0;Withhold</p>
          </list-item>
          <list-item>
            <p>Confirmed SJS, TEN, or DRESS: Permanently discontinue</p>
          </list-item>
        </list>
        <p>Myocarditis or pericarditis:</p>
        <list list-type="bullet">
          <list-item>
            <p>Grade 2, 3, or 4: Permanently discontinue</p>
          </list-item>
        </list>
        <p>Neurological toxicity:</p>
        <list list-type="bullet">
          <list-item>
            <p>Grade 2: Withhold<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a617b089-ce66-464b-987b-b45d029b4d6f#footnote-2">*</ext-link></p>
          </list-item>
          <list-item>
            <p>Grade 3 or 4: Permanently discontinue</p>
          </list-item>
        </list>
        <p>
<bold>Other adverse reactions</bold>
</p>
        <p>Infusion-related reactions</p>
        <list list-type="bullet">
          <list-item>
            <p>Grade 1 or 2:&#x000a0;Hold or slow the injection rate; premedication&#x000a0;with antipyretics and antihistamines may be considered for subsequent doses.</p>
          </list-item>
          <list-item>
            <p>Grade 3 or 4: Permanently discontinue</p>
          </list-item>
        </list>
        <p>DRESS = Drug rash with eosinophilia and systemic symptoms, SJS = Stevens-Johnson syndrome, TEN = toxic epidermal necrolysis; Based on Common Terminology Criteria for Adverse Events (CTCAE), version 5;&#x000a0;<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a617b089-ce66-464b-987b-b45d029b4d6f#footnote-reference-2">&#x02020;</ext-link>&#x000a0;Resume in patients with complete or partial resolution (Grade 0 to 1) after corticosteroid taper. Permanently discontinue if there is no partial or full resolution within 12 weeks of initiating steroids or inability to reduce prednisone to 10 mg daily or less (or equivalent) within 12 weeks of initiating steroids.</p>
        <p>
<bold>Complications of allogeneic HSCT</bold>
</p>
        <p>Assess the benefits and risks of using a PD-1/PD-L1 blocking antibody before or after allogeneic hematopoietic stem cell transplantation (HSCT).&#x000a0;Monitor patients closely for signs of transplant-related complications and take action as needed.</p>
      </sec>
      <sec id="article-130748.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Patients receiving atezolizumab are at risk of developing immune-mediated adverse reactions anytime during therapy and after treatment discontinuation. Early identification and management of imAEs are crucial&#x000a0;for patients&#x000a0;undergoing atezolizumab therapy.<xref ref-type="bibr" rid="article-130748.r15">[15]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Patients should be monitored for signs and symptoms of exfoliative dermatological manifestations, autoimmune colitis, endocrinopathies, and immune-mediated neurological and cardiovascular involvement.</p>
          </list-item>
          <list-item>
            <p>Laboratory tests such as blood glucose level, renal function, liver function, and thyroid function should be performed at baseline before the initiation of treatment and during treatment to evaluate for new-onset diabetes and adverse reactions such as immune-mediated nephritis, immune-mediated hepatitis, and immune-mediated thyroid dysfunction, respectively.</p>
          </list-item>
          <list-item>
            <p>Atezolizumab must be held for patients experiencing grade 2 immune-mediated adverse reactions and should be permanently discontinued&#x000a0;for&#x000a0;grade 3 and 4 immune-mediated adverse reactions, unless indicated by the oncology team.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-130748.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>There is no available data regarding the safety of atezolizumab in pediatric patients and pregnant or breastfeeding women.<xref ref-type="bibr" rid="article-130748.r12">[12]</xref><xref ref-type="bibr" rid="article-130748.r11">[11]</xref> There is also no available data about the drug-drug interaction potential of atezolizumab.<xref ref-type="bibr" rid="article-130748.r13">[13]</xref></p>
        <p>
<bold>Immune-mediated colitis</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Grade 1 colitis should be treated with symptomatic management.</p>
          </list-item>
          <list-item>
            <p>Atezolizumab must be held&#x000a0;for patients experiencing&#x000a0;grade 2 and 3 colitis, and patients should be started on steroids with a slow taper.</p>
          </list-item>
          <list-item>
            <p>Atezolizumab should be permanently discontinued&#x000a0;for patients experiencing&#x000a0;grade 4 colitis.</p>
          </list-item>
        </list>
        <p>
<bold>Immune-mediated pneumonitis</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Tapering corticosteroids is recommended if there is evidence of pneumonitis or interstitial lung disease on lung imaging.</p>
          </list-item>
          <list-item>
            <p>Atezolizumab should be held for grade 2 pneumonitis and permanently discontinued if there is evidence of grade 3 or 4 pneumonitis.</p>
          </list-item>
        </list>
        <p>
<bold>Immune-mediated hepatitis</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>After ruling out viral hepatitis and other etiologies of elevated liver function tests, atezolizumab must be held&#x000a0;for patients experiencing Grade 2 hepatitis. Patients should be started on oral or IV steroids followed by a slow taper.</p>
          </list-item>
          <list-item>
            <p>Atezolizumab must be permanently discontinued&#x000a0;for patients experiencing Grade 3 and 4 immune-mediated hepatitis; these patients should be started on IV steroids.</p>
          </list-item>
        </list>
        <p>
<bold>Immune-mediated endocrinopathies</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>&#x000a0;Thyroid disorders
<list list-type="bullet"><list-item><p>If clinically indicated, consider thyroid hormone replacement therapy in hypothyroidism or medical management of hyperthyroidism.</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Adrenal insufficiency/hypophysitis
<list list-type="bullet"><list-item><p>Consider initiating stress dose corticosteroids and hormone replacement therapy as clinically indicated.</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Type 1 diabetes
<list list-type="bullet"><list-item><p>Consider starting insulin if indicated.</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Atezolizumab should be held&#x000a0;for patients with&#x000a0;grade 2 to 4 endocrinopathies.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Immune-mediated renal dysfunction and nephritis
<list list-type="bullet"><list-item><p>Atezolizumab should be held&#x000a0;for patients with grade 2 toxicity or higher, and corticosteroid administration should be considered.</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Immune-mediated cutaneous adverse reactions
<list list-type="bullet"><list-item><p>Topical steroids are indicated for grade 1 or 2 toxicity.</p></list-item><list-item><p>Atezolizumab must be held in grade 2 and 3 toxicity; patients with grade 2 toxicity should be treated with&#x000a0;oral steroids.</p></list-item><list-item><p>Atezolizumab must be permanently discontinued in patients with grade 4 immune toxicity, and patients should be treated with IV steroids in an intensive care unit (ICU).</p></list-item></list>
</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-130748.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Given its propensity to cause immune-mediated adverse reactions, the clinical use of atezolizumab requires an interprofessional team approach of healthcare professionals to enhance safety and efficacy. Clinicians prescribing this drug should educate their patients about the immediate and long-term adverse reactions. The clinical pharmacist and the nurse administering the drug infusion to the patients about the mechanism of action, recommended doses, and infusion-related adverse reactions of atezolizumab. Laboratory tests must be performed and reviewed before and during treatment with atezolizumab. This interprofessional approach will yield optimal therapeutic results.</p>
        <p>There should be close communication between the ordering clinicians, the pharmacist, and the nurse about any infusion-related reactions or laboratory abnormalities related to the drug. Signs and symptoms of immune-mediated adverse reactions during treatment or long after discontinuation of atezolizumab should be monitored, and appropriate clinical investigations must be performed to rule out other etiologies. Detailed prescribing information and essential dose management information specific to adverse reactions should always be available for review. Applicable clinical specialties must be promptly consulted. Such a holistic approach would lead to timely identification and management of this drug's potential adverse effects, resulting in improved outcomes.</p>
      </sec>
      <sec id="article-130748.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=130748&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=130748">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/130748/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=130748">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-130748.s11">
        <title>References</title>
        <ref id="article-130748.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Horn</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Mansfield</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Szcz&#x00119;sna</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Havel</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Krzakowski</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hochmair</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Huemer</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Losonczy</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Nishio</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Reck</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mok</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Lam</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shames</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ding</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Lopez-Chavez</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kabbinavar</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Sandler</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>SV</given-names>
              </name>
              <collab>IMpower133 Study Group</collab>
            </person-group>
            <article-title>First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.</article-title>
            <source>N Engl J Med</source>
            <year>2018</year>
            <month>Dec</month>
            <day>06</day>
            <volume>379</volume>
            <issue>23</issue>
            <fpage>2220</fpage>
            <page-range>2220-2229</page-range>
            <pub-id pub-id-type="pmid">30280641</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130748.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Herbst</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Giaccone</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>de Marinis</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Reinmuth</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Vergnenegre</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Barrios</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Morise</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Felip</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Andric</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Geater</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>&#x000d6;zg&#x000fc;ro&#x0011f;lu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zou</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Sandler</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Enquist</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Komatsubara</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Deng</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kuriki</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Wen</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>McCleland</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mocci</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jassem</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Spigel</surname>
                <given-names>DR</given-names>
              </name>
            </person-group>
            <article-title>Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC.</article-title>
            <source>N Engl J Med</source>
            <year>2020</year>
            <month>Oct</month>
            <day>01</day>
            <volume>383</volume>
            <issue>14</issue>
            <fpage>1328</fpage>
            <page-range>1328-1339</page-range>
            <pub-id pub-id-type="pmid">32997907</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130748.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Socinski</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Jotte</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Cappuzzo</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Orlandi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Stroyakovskiy</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Nogami</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Rodr&#x000ed;guez-Abreu</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Moro-Sibilot</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Barlesi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Finley</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kelsch</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Coleman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Deng</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kowanetz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lopez-Chavez</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sandler</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Reck</surname>
                <given-names>M</given-names>
              </name>
              <collab>IMpower150 Study Group</collab>
            </person-group>
            <article-title>Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.</article-title>
            <source>N Engl J Med</source>
            <year>2018</year>
            <month>Jun</month>
            <day>14</day>
            <volume>378</volume>
            <issue>24</issue>
            <fpage>2288</fpage>
            <page-range>2288-2301</page-range>
            <pub-id pub-id-type="pmid">29863955</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130748.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Finn</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Qin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ikeda</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Galle</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Ducreux</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>TY</given-names>
              </name>
              <name>
                <surname>Kudo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Breder</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Merle</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kaseb</surname>
                <given-names>AO</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Verret</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>DZ</given-names>
              </name>
              <name>
                <surname>Hernandez</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mulla</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>HY</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>AX</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>AL</given-names>
              </name>
              <collab>IMbrave150 Investigators</collab>
            </person-group>
            <article-title>Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.</article-title>
            <source>N Engl J Med</source>
            <year>2020</year>
            <month>May</month>
            <day>14</day>
            <volume>382</volume>
            <issue>20</issue>
            <fpage>1894</fpage>
            <page-range>1894-1905</page-range>
            <pub-id pub-id-type="pmid">32402160</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130748.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gutzmer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Stroyakovskiy</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gogas</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Robert</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lewis</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Protsenko</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pereira</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Eigentler</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Rutkowski</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Demidov</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Manikhas</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Yan</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Uyei</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>McNally</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>McArthur</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Ascierto</surname>
                <given-names>PA</given-names>
              </name>
            </person-group>
            <article-title>Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF<sup>V600</sup> mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial.</article-title>
            <source>Lancet</source>
            <year>2020</year>
            <month>Jun</month>
            <day>13</day>
            <volume>395</volume>
            <issue>10240</issue>
            <fpage>1835</fpage>
            <page-range>1835-1844</page-range>
            <pub-id pub-id-type="pmid">32534646</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130748.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schmid</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Rugo</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Adams</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Schneeweiss</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Barrios</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Iwata</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Di&#x000e9;ras</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Henschel</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Molinero</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Chui</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Maiya</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Husain</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Winer</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Loi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Emens</surname>
                <given-names>LA</given-names>
              </name>
              <collab>IMpassion130 Investigators</collab>
            </person-group>
            <article-title>Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial.</article-title>
            <source>Lancet Oncol</source>
            <year>2020</year>
            <month>Jan</month>
            <volume>21</volume>
            <issue>1</issue>
            <fpage>44</fpage>
            <page-range>44-59</page-range>
            <pub-id pub-id-type="pmid">31786121</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130748.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Balar</surname>
                <given-names>AV</given-names>
              </name>
              <name>
                <surname>Galsky</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Rosenberg</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Powles</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Petrylak</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Bellmunt</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Loriot</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Necchi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hoffman-Censits</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Perez-Gracia</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Dawson</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>van der Heijden</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Dreicer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Srinivas</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Retz</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Joseph</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Drakaki</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vaishampayan</surname>
                <given-names>UN</given-names>
              </name>
              <name>
                <surname>Sridhar</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Quinn</surname>
                <given-names>DI</given-names>
              </name>
              <name>
                <surname>Dur&#x000e1;n</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Shaffer</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Eigl</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Grivas</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>EY</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kadel</surname>
                <given-names>EE</given-names>
              </name>
              <name>
                <surname>Boyd</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Bourgon</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hegde</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Mariathasan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Th&#x000e5;str&#x000f6;m</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Abidoye</surname>
                <given-names>OO</given-names>
              </name>
              <name>
                <surname>Fine</surname>
                <given-names>GD</given-names>
              </name>
              <name>
                <surname>Bajorin</surname>
                <given-names>DF</given-names>
              </name>
              <collab>IMvigor210 Study Group</collab>
            </person-group>
            <article-title>Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.</article-title>
            <source>Lancet</source>
            <year>2017</year>
            <month>Jan</month>
            <day>07</day>
            <volume>389</volume>
            <issue>10064</issue>
            <fpage>67</fpage>
            <page-range>67-76</page-range>
            <pub-id pub-id-type="pmid">27939400</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130748.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Necchi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Joseph</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Loriot</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Hoffman-Censits</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Perez-Gracia</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Petrylak</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Derleth</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Tayama</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Ding</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kaiser</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rosenberg</surname>
                <given-names>JE</given-names>
              </name>
            </person-group>
            <article-title>Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study.</article-title>
            <source>Ann Oncol</source>
            <year>2017</year>
            <month>Dec</month>
            <day>01</day>
            <volume>28</volume>
            <issue>12</issue>
            <fpage>3044</fpage>
            <page-range>3044-3050</page-range>
            <pub-id pub-id-type="pmid">28950298</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130748.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Herbst</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Soria</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Kowanetz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fine</surname>
                <given-names>GD</given-names>
              </name>
              <name>
                <surname>Hamid</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Gordon</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Sosman</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>McDermott</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Powderly</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Gettinger</surname>
                <given-names>SN</given-names>
              </name>
              <name>
                <surname>Kohrt</surname>
                <given-names>HE</given-names>
              </name>
              <name>
                <surname>Horn</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lawrence</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Rost</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Leabman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Xiao</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Mokatrin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Koeppen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hegde</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Mellman</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Hodi</surname>
                <given-names>FS</given-names>
              </name>
            </person-group>
            <article-title>Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.</article-title>
            <source>Nature</source>
            <year>2014</year>
            <month>Nov</month>
            <day>27</day>
            <volume>515</volume>
            <issue>7528</issue>
            <fpage>563</fpage>
            <page-range>563-7</page-range>
            <pub-id pub-id-type="pmid">25428504</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130748.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Irving</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Hodi</surname>
                <given-names>FS</given-names>
              </name>
            </person-group>
            <article-title>Molecular pathways: next-generation immunotherapy--inhibiting programmed death-ligand 1 and programmed death-1.</article-title>
            <source>Clin Cancer Res</source>
            <year>2012</year>
            <month>Dec</month>
            <day>15</day>
            <volume>18</volume>
            <issue>24</issue>
            <fpage>6580</fpage>
            <page-range>6580-7</page-range>
            <pub-id pub-id-type="pmid">23087408</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130748.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hoffner</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Leighl</surname>
                <given-names>NB</given-names>
              </name>
              <name>
                <surname>Davies</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Toxicity management with combination chemotherapy and programmed death 1/programmed death ligand 1 inhibitor therapy in advanced lung cancer.</article-title>
            <source>Cancer Treat Rev</source>
            <year>2020</year>
            <month>Apr</month>
            <volume>85</volume>
            <fpage>101979</fpage>
            <pub-id pub-id-type="pmid">32078962</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130748.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reddy</surname>
                <given-names>HG</given-names>
              </name>
              <name>
                <surname>Schneider</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Tai</surname>
                <given-names>AW</given-names>
              </name>
            </person-group>
            <article-title>Immune Checkpoint Inhibitor-Associated Colitis and Hepatitis.</article-title>
            <source>Clin Transl Gastroenterol</source>
            <year>2018</year>
            <month>Sep</month>
            <day>19</day>
            <volume>9</volume>
            <issue>9</issue>
            <fpage>180</fpage>
            <pub-id pub-id-type="pmid">30228268</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130748.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Haanen</surname>
                <given-names>JBAG</given-names>
              </name>
              <name>
                <surname>Carbonnel</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Robert</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kerr</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Peters</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Larkin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jordan</surname>
                <given-names>K</given-names>
              </name>
              <collab>ESMO Guidelines Committee</collab>
            </person-group>
            <article-title>Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.</article-title>
            <source>Ann Oncol</source>
            <year>2017</year>
            <month>Jul</month>
            <day>01</day>
            <volume>28</volume>
            <issue>suppl_4</issue>
            <fpage>iv119</fpage>
            <page-range>iv119-iv142</page-range>
            <pub-id pub-id-type="pmid">28881921</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130748.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Suzman</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Agrawal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ning</surname>
                <given-names>YM</given-names>
              </name>
              <name>
                <surname>Maher</surname>
                <given-names>VE</given-names>
              </name>
              <name>
                <surname>Fernandes</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Karuri</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sridhara</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Schroeder</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Goldberg</surname>
                <given-names>KB</given-names>
              </name>
              <name>
                <surname>Ibrahim</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>McKee</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Pazdur</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Beaver</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin-Containing Chemotherapy.</article-title>
            <source>Oncologist</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>24</volume>
            <issue>4</issue>
            <fpage>563</fpage>
            <page-range>563-569</page-range>
            <pub-id pub-id-type="pmid">30541754</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130748.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schmalz</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Jacob</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ammann</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Liss</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Iivanainen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kammermann</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Koivunen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Popescu</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Digital Monitoring and Management of Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Treated With Cancer Immunotherapy and Its Impact on Quality of Clinical Care: Interview and Survey Study Among Health Care Professionals and Patients.</article-title>
            <source>J Med Internet Res</source>
            <year>2020</year>
            <month>Dec</month>
            <day>21</day>
            <volume>22</volume>
            <issue>12</issue>
            <fpage>e18655</fpage>
            <pub-id pub-id-type="pmid">33346738</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
